CN4 Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab Versus Chlorambucil PLUS Obinutuzumab for Treatment-Na ïve Chronic Lymphocytic Leukemia (ELEVATE-TN)

Report patient-reported outcomes of fatigue and health-related quality of life (HRQoL) from the randomized, phase 3, ELEVATE-TN study (NCT02475681) in patients with treatment-na ïve chronic lymphocytic leukemia (CLL).

Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: P. Walker, J.P. Sharman, W. Jurczak, T. Munir, V. Banerji, S. Coutre, J. Woyach, G. Salles, W.G. Wierda, P. Patel, M.H. Wang, U. Emeribe, E. Flood, J.C. Byrd, P. Ghia Source Type: research